Compare WFG & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WFG | ERAS |
|---|---|---|
| Founded | 1955 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.0B |
| IPO Year | 2007 | 2021 |
| Metric | WFG | ERAS |
|---|---|---|
| Price | $69.68 | $18.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $89.50 | $14.25 |
| AVG Volume (30 Days) | 212.6K | ★ 4.3M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.05 | N/A |
| Revenue Next Year | $10.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.34 | $1.33 |
| 52 Week High | $76.99 | $24.28 |
| Indicator | WFG | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | N/A |
| Support Level | $63.81 | N/A |
| Resistance Level | $72.72 | N/A |
| Average True Range (ATR) | 2.37 | 0.00 |
| MACD | 0.36 | 0.00 |
| Stochastic Oscillator | 98.55 | 0.00 |
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.